Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro

Norio Ogawa, Ken ichi Tanaka, Masato Asanuma, Motoko Kawai, Toshiki Masumizu, Masahiro Kohno, Akitane Mori

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Pretreatment with bromocriptine (5 mg/kg, i.p., 7 days) completely protected against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine, but similar pretreatment with l-DOPA/carbidopa (75/7.5 mg/kg, i.p., 7 days) showed only partial protective effect. Furthermore, in an in vitro system that generated ·OH from FeSO4-H2O2, bromocriptine dose-dependently reduced the number of ·OH radicals. These findings indicate that bromocriptine has a neuroprotective effect against neurotoxins such as 6-hydroxydopamine, probably due, in part, to its hydroxyl radical scavenging activity and inhibiting effect on dopamine turnover rate. This suggests that early introduction of bromocriptine in the therapy of Parkinson's disease may be superior to treatment with l-DOPA alone.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalBrain Research
Volume657
Issue number1-2
DOIs
Publication statusPublished - Sep 19 1994

Fingerprint

Bromocriptine
Oxidopamine
Hydroxyl Radical
Free Radicals
Dopamine
Carbidopa
Intraventricular Injections
Corpus Striatum
Desipramine
Neurotoxins
Neuroprotective Agents
Parkinson Disease
In Vitro Techniques
Therapeutics

Keywords

  • 6-Hydroxydopamine
  • Bromocriptine
  • Free radical
  • Hydroxyl radical
  • l-DOPA
  • Neuroprotection
  • Parkinson's disease

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. / Ogawa, Norio; Tanaka, Ken ichi; Asanuma, Masato; Kawai, Motoko; Masumizu, Toshiki; Kohno, Masahiro; Mori, Akitane.

In: Brain Research, Vol. 657, No. 1-2, 19.09.1994, p. 207-213.

Research output: Contribution to journalArticle

Ogawa, Norio ; Tanaka, Ken ichi ; Asanuma, Masato ; Kawai, Motoko ; Masumizu, Toshiki ; Kohno, Masahiro ; Mori, Akitane. / Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. In: Brain Research. 1994 ; Vol. 657, No. 1-2. pp. 207-213.
@article{6e53e06902674d32bbdd0d06292698e5,
title = "Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro",
abstract = "Pretreatment with bromocriptine (5 mg/kg, i.p., 7 days) completely protected against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine, but similar pretreatment with l-DOPA/carbidopa (75/7.5 mg/kg, i.p., 7 days) showed only partial protective effect. Furthermore, in an in vitro system that generated ·OH from FeSO4-H2O2, bromocriptine dose-dependently reduced the number of ·OH radicals. These findings indicate that bromocriptine has a neuroprotective effect against neurotoxins such as 6-hydroxydopamine, probably due, in part, to its hydroxyl radical scavenging activity and inhibiting effect on dopamine turnover rate. This suggests that early introduction of bromocriptine in the therapy of Parkinson's disease may be superior to treatment with l-DOPA alone.",
keywords = "6-Hydroxydopamine, Bromocriptine, Free radical, Hydroxyl radical, l-DOPA, Neuroprotection, Parkinson's disease",
author = "Norio Ogawa and Tanaka, {Ken ichi} and Masato Asanuma and Motoko Kawai and Toshiki Masumizu and Masahiro Kohno and Akitane Mori",
year = "1994",
month = "9",
day = "19",
doi = "10.1016/0006-8993(94)90969-5",
language = "English",
volume = "657",
pages = "207--213",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro

AU - Ogawa, Norio

AU - Tanaka, Ken ichi

AU - Asanuma, Masato

AU - Kawai, Motoko

AU - Masumizu, Toshiki

AU - Kohno, Masahiro

AU - Mori, Akitane

PY - 1994/9/19

Y1 - 1994/9/19

N2 - Pretreatment with bromocriptine (5 mg/kg, i.p., 7 days) completely protected against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine, but similar pretreatment with l-DOPA/carbidopa (75/7.5 mg/kg, i.p., 7 days) showed only partial protective effect. Furthermore, in an in vitro system that generated ·OH from FeSO4-H2O2, bromocriptine dose-dependently reduced the number of ·OH radicals. These findings indicate that bromocriptine has a neuroprotective effect against neurotoxins such as 6-hydroxydopamine, probably due, in part, to its hydroxyl radical scavenging activity and inhibiting effect on dopamine turnover rate. This suggests that early introduction of bromocriptine in the therapy of Parkinson's disease may be superior to treatment with l-DOPA alone.

AB - Pretreatment with bromocriptine (5 mg/kg, i.p., 7 days) completely protected against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine, but similar pretreatment with l-DOPA/carbidopa (75/7.5 mg/kg, i.p., 7 days) showed only partial protective effect. Furthermore, in an in vitro system that generated ·OH from FeSO4-H2O2, bromocriptine dose-dependently reduced the number of ·OH radicals. These findings indicate that bromocriptine has a neuroprotective effect against neurotoxins such as 6-hydroxydopamine, probably due, in part, to its hydroxyl radical scavenging activity and inhibiting effect on dopamine turnover rate. This suggests that early introduction of bromocriptine in the therapy of Parkinson's disease may be superior to treatment with l-DOPA alone.

KW - 6-Hydroxydopamine

KW - Bromocriptine

KW - Free radical

KW - Hydroxyl radical

KW - l-DOPA

KW - Neuroprotection

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0028068121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028068121&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(94)90969-5

DO - 10.1016/0006-8993(94)90969-5

M3 - Article

C2 - 7820619

AN - SCOPUS:0028068121

VL - 657

SP - 207

EP - 213

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -